Pulmicort Dosage & Drug Information

Concise Prescribing Info Bahasa Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Budesonide

Indications/Uses

Bronchial asthma. Moderate to severe acute laryngotracheobronchitis (croup) in infants & childn, acute exacerbation of asthma, exacerbations of COPD.

Click to view Pulmicort detailed prescribing information

Dosage/Direction for Use

Individualized dosage. Bronchial asthma Adult & childn ≥12 yr Initially 1-2 mg twice daily. Maintenance: 0.5-1 mg twice daily. Childn 3 mth-12 yr Initially 0.5-1 mg twice daily. Maintenance: 0.25-0.5 mg twice daily. Acute laryngotracheobronchitis (croup) Infant & childn 2 mg of nebulised as single administration. Acute exacerbations of asthma Adult 4-8 mg divided into 1-4 administrations. May be further increased in very severe cases. Max: 4 mg at one occasion. Can be continued until clinical improvement, max 10 days. Childn (6 mth-17 yr) 1.5-4 mg, up to 6 mg in childn ≥5 yr. Daily dose can be divided into 1-4 administrations. Max: 3 mg at one occasion. Can be continued until clinical improvement, max 10 days. Exacerbations of COPD 4-8 mg divided into 2-4 administrations, until clinical improvement, but max 10 days.

Click to view Pulmicort detailed prescribing information

Overdosage

View Pulmicort overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity.

Click to view Pulmicort detailed prescribing information

Special Precautions

Not indicated for rapid relief of bronchospasm. Not suitable as sole therapy for status asthmaticus or other acute asthma exacerbations. HPA axis suppression & adrenal insufficiency, bone density, growth; infections & TB; impaired liver function. Do not use w/ +ve pressure delivery systems. Pregnancy.

Click to view Pulmicort detailed prescribing information

Use In Pregnancy & Lactation

Click to view Pulmicort detailed prescribing information

Adverse Reactions

Mild irritation in the throat, coughing, hoarseness; Candida infection in the oropharynx. Sore throat, tongue & mouth irritation, dry mouth.

Click to view Pulmicort detailed prescribing information

Drug Interactions

Increased systemic exposure w/ CYP3A4 inhibitors eg, ketoconazole, itraconazole.

Click to view Pulmicort detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Pulmicort detailed prescribing information

Storage

View Pulmicort storage conditions for details to ensure optimal shelf-life.

Description

View Pulmicort description for details of the chemical structure and excipients (inactive components).

Action

View Pulmicort mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Antiasthmatic & COPD Preparations

ATC Classification

R03BA02 - budesonide ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids.

Regulatory Classification

Presentation/Packing

Form

Pulmicort respules 0.25 mg/mL

Packing/Price

2 mL x 20 × 1's (Rp566,211/boks)

Form

Pulmicort respules 0.5 mg/mL

Packing/Price

2 mL x 20 × 1's (Rp702,258/boks)

Pulmicort

budesonide

Manufacturer:

AstraZeneca